 |
|
Fair and adequate reimbursement is vital to developing life-saving medical treatments
June 18, 2008SNM issues response to CMS's reclassification of diagnostic radiopharmaceuticals
RESTON, Va.-Reimbursement of molecular imaging and therapies-leading to the early detection and diagnosis of many life-threatening diseases-remains an urgent and critical need as consumers face ever-increasing healthcare costs. The Centers for Medicare and Medicaid Services (CMS) needs to provide fair and adequate reimbursement for effective diagnostic techniques and life-saving medical therapies-yet currently, diagnostic radiopharmaceuticals are not adequately reimbursed. To address this pressing problem, SNM has issued proposed recommendations and rationale for reforming radiopharmaceutical reimbursement under Medicare.
Despite statutory language in the Social Security Act clearly defining radiopharmaceuticals as "specified covered outpatient drugs," CMS recently reclassified diagnostic radiopharmaceuticals as "supplies" instead of "drugs." This distinction has bundled payment for diagnostic radiopharmaceuticals into the payment for nuclear medicine procedures, thus threatening Medicare and other patient access to these critical diagnostic drugs.
"Treatments exist today that can radically improve the prognosis for patients suffering from many devastating diseases, and yet reimbursement by CMS for these drugs is sometimes less than half the actual cost of producing them," said 2008-09 SNM President Robert W. Atcher, Ph.D., M.B.A. "As we develop new therapeutic radiopharmaceuticals that have the potential to dramatically change disease outcomes, we need to ensure that they will be adequately reimbursed in order to be effectively utilized."
To address this issue and to ensure that Medicare beneficiaries continue to have access to diagnostic radiopharmaceuticals, SNM has issued the following recommendations:
1. All radiopharmaceuticals should be recognized and treated as drugs, not supplies.
2. CMS should continue to reimburse radiopharmaceuticals at charges reduced to cost in 2008 while working with the nuclear medicine industry (nuclear pharmacies and manufacturers) to develop standard payment methodology based on the average radiopharmaceutical invoice price at the distributor or nuclear pharmacy level (patterned after the average sales price model for drugs).
3. All radiopharmaceuticals should qualify for the same bundling threshold in 2008 ($60.00) as all other drugs.
4. CMS should accept and utilize external data sources to identify and appropriately reimburse radiopharmaceuticals under HOPPS, as the agency does for all other drugs. The most accurate sources of radiopharmaceutical cost data are nuclear pharmacies and manufacturers.
Nuclear medicine procedures are safe, painless and cost-effective techniques used to diagnose and treat disease. These imaging techniques are essential to the management of many serious diseases, including heart disease and cancer, as they provide specific information about physiologic, metabolic and other functional activities in the body or its pathology and allow for highly effective targeted therapy. For more information on SNM's policy statement on reforming radiopharmaceutical reimbursement under Medicare, please visit www.snm.org/cmspolicy.
Society of Nuclear Medicine
"Treatments exist today that can radically improve the prognosis for patients suffering from many devastating diseases, and yet reimbursement by CMS for these drugs is sometimes less than half the actual cost of producing them," said 2008-09 SNM President Robert W. Atcher, Ph.D., M.B.A. "As we develop new therapeutic radiopharmaceuticals that have the potential to dramatically change disease outcomes, we need to ensure that they will be adequately reimbursed in order to be effectively utilized."
To address this issue and to ensure that Medicare beneficiaries continue to have access to diagnostic radiopharmaceuticals, SNM has issued the following recommendations:
1. All radiopharmaceuticals should be recognized and treated as drugs, not supplies.
2. CMS should continue to reimburse radiopharmaceuticals at charges reduced to cost in 2008 while working with the nuclear medicine industry (nuclear pharmacies and manufacturers) to develop standard payment methodology based on the average radiopharmaceutical invoice price at the distributor or nuclear pharmacy level (patterned after the average sales price model for drugs).
3. All radiopharmaceuticals should qualify for the same bundling threshold in 2008 ($60.00) as all other drugs.
4. CMS should accept and utilize external data sources to identify and appropriately reimburse radiopharmaceuticals under HOPPS, as the agency does for all other drugs. The most accurate sources of radiopharmaceutical cost data are nuclear pharmacies and manufacturers.
Nuclear medicine procedures are safe, painless and cost-effective techniques used to diagnose and treat disease. These imaging techniques are essential to the management of many serious diseases, including heart disease and cancer, as they provide specific information about physiologic, metabolic and other functional activities in the body or its pathology and allow for highly effective targeted therapy. For more information on SNM's policy statement on reforming radiopharmaceutical reimbursement under Medicare, please visit www.snm.org/cmspolicy.
Society of Nuclear Medicine
First semiconductor-based PET scanner demonstrates potential to aid in early diagnosis of disease
Evaluations of the first-ever prototype positron emission tomography (PET) brain scanner that uses semiconductor detectors indicate that the scanner could advance the quality and spatial resolution of PET imaging, according to researchers at SNM's 55th Annual Meeting.
Study recommends development of standards for pediatric doses in nuclear medicine
Results of a recent survey of 13 pediatric hospitals in North America show a lack of universally applied standards for administering radiopharmaceutical doses to children undergoing nuclear medicine examinations, according to an article in the June issue of The Journal of Nuclear Medicine.
Patients Need To Know that Nuclear Medicine Procedures Can Trigger Radiation Alarms
Twenty million nuclear medicine procedures that detect and evaluate heart disease, brain disorders and cancer-and that use radiopharmaceuticals to treat overactive thyroids and some cancers-are performed each year.
Predicting PET Imaging's Future: Diagnosing and Treating Diseases ASAP
Imagine a new world of detecting and diagnosing diseases sooner-even before any symptoms are present. Consider the possibility of receiving individualized, targeted molecular, cellular or genetic medical treatment as soon as possible and of undergoing scanning that can quickly tell your doctor whether your treatment is working.
EU joint effort leads to better cancer diagnosis in northern Italy
Since March 16, one of the most important drugs used primarily to diagnose cancer was made available for commercial production and distribution in some hospitals and treatment centres in northern Italy. The availability of the drug, 18F-Fludeoxyglucose (18F-FDG), is the result of a joint agreement between the Institute for Health and Consumer Protection (IHCP), which is part of the European Union's Joint Research Centre (JRC), and the private company, Amersham Health. 18F-FDG is of one of the most important radiopharmaceuticals used in Nuclear Medicine, mainly for cancer diagnosis using medical imaging technology known as Positron Emission Tomography (PET). The Cyclotron facility at the IHCP
More Radiopharmaceuticals News Articles
 | Fundamentals of Nuclear Pharmacy by Gopal B. Saha This is the classic text/reference of nuclear pharmacy, thoroughly updated and judiciously expanded. Generously supplemented with charts, tables, and more than 100 illustrations throughout, each chapter provides the reader with well-delineated descriptions, from the basic autotomic structure through the clinical uses of radiopharmaceuticals. Previous editions were unanimously priased for their... |
 | Radiopharmaceuticals in Nuclear Pharmacy & Nuclear Medicine by Richard J. Kowalsky, Steven Falen, Richard Kowalsky This text covers all subject areas needed to become licensed as an authorized nuclear pharmacist. Divided into two major sections: basic science concepts and clinical applications, the Second Edition has been updated to reflect new radiopharmaceuticals and applications in nuclear medicine as well as include two new chapters on Monoclonal Antibodies and Therapeutic... |
 | Nuclear Medicine Technology: Procedures and Quick Reference by Pete Shackett Completely updated with the latest advances in imaging technology, this quick-reference manual is the only procedures guide specifically geared to nuclear medicine technologists. It provides detailed, easy-to-follow instructions for 61 scan procedures, including listings of possible artifacts and problems that may arise during each scan. An extensive quick-reference section includes conversion... |
 | Diagnostic Nuclear Medicine (Medical Radiology / Diagnostic Imaging) The field of nuclear medicine is undergoing rapid expansion, and is evolving into diagnostic molecular imaging. During recent years, dual-modality imaging with PET/CT has gained acceptance and this is currently the fastest-growing technique for oncological imaging applications. The glucose analogue FDG has held its place in diagnostic oncology, assessment of myocardial viability and diagnosis of... |
 | Technetium-99m Pharmaceuticals: Preparation and Quality Control in Nuclear Medicine Radioactive drug development is a multi-disciplinary task, therefore, in a concerted effort, dedicated scientists and experts from different fields of specialisation have contributed to this book. It is presented in two sections. Section 1 contains basic principles and methods used for analysis, information on the chemistry of technetium and on radiopharmaceuticals labelled with technetium-99m,... |
| Biological Models in Radiopharmaceutical Development (Developments in Nuclear Medicine) by R.M. Lambrecht This comprehensive resource guide reflects an analysis of the world literature, for the period between 1983 and June, 1995. It provides a succinct overview of the current status of biological models that can facilitate advances in the development of drugs and radiopharmaceuticals and allows rational choices of the appropriate models for investigations specific to understanding disease... | |
 | Practical Nuclear Medicine Nuclear medicine plays a crucial role in patient care, and this book is an essential guide for all practitioners to the many techniques that inform clinical management. The first part covers the scientific basis of nuclear medicine, the rest of the book deals with clinical applications. Diagnostic imaging has an increasingly important role in patient management and, despite advances in other... |
 | ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals by ICRP This publication presents biokinetic models and best estimates of biokinetic data for some 120 individual radiopharmaceuticals, giving estimated absorbed doses, including the range of variation to be expected in pathological states, for adults, children and the fetus. Absorbed dose estimates are needed in clinical diagnostic work for judging the risk associated with the use of specific... |
 | Mird Cellular S. Values: Self-Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Monoenergetic Electron and Alpha Particle Emitters Incorporated into by Roger W. Howell, Lionel G. Bouchet, Wesley E. Bolch, Dandamudi V. Rao |
 | Textbook of Radiopharmacy (Nuclear Medicine, Vol 3) by C. B. Sampson This second edition now includes practical information on drug enhancement of nuclear medicine studies; radiopharmaceuticals as therapeutic agents; pharmacokinetics and a section on current radiopharmaceutical research.This book begins with the basic scientific principles of radiation physics, generator systems and preparation of radiopharmaceuticals. It deals with methods of localization of... |
| © 2008 BrightSurf.com |